Company Overview and News

0
Venus Metals obtains high-grade vanadium concentrate in Youanmi metallurgical tests

2018-07-19 proactiveinvestors.com.au
Venus Metals Corporation Ltd (ASX:VMC) has produced high-grade vanadium-enriched magnetic concentrate from 11 historical diamond drill core samples at its Youanmi Vanadium Project in Western Australia.
WVL VMC

0
Venus Metals Corporation increases gold resource at Youanmi project

2018-06-29 proactiveinvestors.com.au
Venus Metals Corporation Ltd (ASX:VMC) has added significant tonnage to its resource estimate for the Youanmi Gold Project in the Murchison region of Western Australia.
VMC

1
Sabre Resources’ vanadium acquisition strategy is strongly supported by market

2018-04-24 proactiveinvestors.com.au
Sabre Resources Limited’s (ASX:SBR) news of its intended acquisition of three vanadium projects in Western Australia has been well received by the market with shares surging 94% to a new 12-month high.
KRC VMC SBR

0
Venus Metals identifies eight priority gold targets in Western Australia

2018-03-23 proactiveinvestors.com.au
Venus Metals Corporation Limited (ASX:VMC) has identified eight priority gold targets for follow-up work at the Youanmi Gold Project in Western Australia’s Mid-West.
VMC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:VMC / VENUS METALS CORPORATION LIMITED on message board site Silicon Investor.

AVMC - aVinci Media Corporation AVMC - aVinci Media Corp.